Impact BioMedical Inc. (IBO)

NYSEAMERICAN: IBO · USD

$3.99

+0.44 (+12.4%)· Recorded snapshot

Market cap	34.1M
Revenue (ttm)	35K
Net income (ttm)	791K
EPS (ttm)	$0.07
Shares out	8.5M
P/E (trailing)	60.2x
Volume	39,661
Beta	2.73

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 35K
Net income (ttm): 791K
EPS (ttm): $0.07
P/E (trailing): 60.2x
Market cap: 34.1M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Trzymaj

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/E60.2

P25 n/aP50 n/aP75 n/a

ROE23.5

P25 n/aP50 n/aP75 n/a

ROIC-22

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All IBO indicators

Market & fundamental data

Available fields

191

Groups with data

Currency

USD

Showing 191 of 191 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001834105
Company name	Impact BioMedical Inc.
Country	United States
Country code	US
CUSIP number	45259L304
Earnings date	2026-11-10
Earnings time	amc
Employees	2
Employees change	1
Employees growth	100%
Enterprise value	$34.1M
Exchange	NYSEAMERICAN
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2018
Industry	Biotechnology
IPO date	2024-09-16
Is primary listing	Yes
Is SPAC	No
ISIN number	US45259L3042
Last 10-K release date	2026-03-11
Last earnings date	2026-08-07
Last refreshed	2026-10-28
Last stock split date	2026-09-23
Last stock split type	Reverse
Market cap	$34.1M
Market cap category	Nano-Cap
Next earnings date	2026-11-10
Options	No
Price	$3.99
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	IBO
U.S. state	Texas
Website	https://www.impactbiomedinc.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	1.66%
EV/Earnings	38.33x
EV/Sales	866.3x
FCF / EV yield	-1.68%
FCF yield	-1.67%
Graham number	1.37052
Graham upside	-61.39%
P/B ratio	2.82x
P/E ratio	60.23x
P/S ratio	866.58x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Operating margin	-14,557.14%
Pretax margin	-5,148.57%
Profit margin	2,260%
Profit per employee	$395,500
Revenue per employee	$17,500
ROA	-17.79%
ROA (5Y)	-6.83%
ROCE	-34.66%
ROE	23.46%
ROE (5Y)	-56.54%
ROIC	-21.97%
SBC / revenue	4,140%
Tax / revenue	-7,371.43%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	3
EPS growth years	1
Gross profit growth (Q)	-66.67%
Net income growth quarters	1
Net income growth years	1
Revenue growth	400%
Revenue growth (Q)	-57.14%
Revenue growth (QoQ)	-57.14%
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Depreciation and amortization	$1.1M
EBIT	$-5.1M
EBITDA	$-4M
EPS	$0.07
FCF per share	$-0.06
Financing cash flow	$-109,000
Free cash flow	$-508,000
Free cash flow minus SBC	$-2M
Gross profit	$-389,000
Income taxes	$-2.6M
Investing cash flow	$3,000
Net borrowing	$-109,000
Net cash flow	$-614,000
Net income	$791,000
Operating cash flow minus SBC	$-2M
Operating income	$-5.1M
Revenue	$35,000
Stock-based compensation	$1.4M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	3
Book value per share	$1.26
Debt / equity	0
Interest coverage	-19.45
Long-term assets	$16.4M
Long-term liabilities	$688,000
Net cash (debt)	$10,000
Net cash / market cap	0.03%
Net debt / equity	-0
Piotroski F-Score	2
Shareholders' equity	$14M
Tangible book value	$-5.7M
Tangible book value per share	$-0.66
Total assets	$16.7M
Total cash	$10,000
Total debt	$0
Total liabilities	$2.7M
WACC	19.29%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0
Current assets	$320,000
Current liabilities	$2M
Current ratio	0.16
Inventory turnover	1.55
Net working capital	$-1.7M
Quick ratio	0
Working capital	$-1.7M
Working capital turnover	-0

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-571.61%
Dividend yield	0%
Shareholder yield	-571.61%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$6.31
1D price change	12.39%
1M price change	-32.16%
1M total return	-32.16%
1W price change	18.12%
1W total return	18.13%
1Y price change	-47.53%
1Y return CAGR	-47.56%
1Y total return	-47.54%
20-day SMA	$3.96
200-day SMA	$6.28
3M price change	-29.2%
3M total return	-29.2%
50-day SMA	$5.23
50-day SMA vs 200-day SMA	50under200
52-week high	$10.48
52-week high date	2026-03-05
52-week low	$2.43
52-week low date	2026-10-16
6M price change	-53.66%
6M total return	-53.66%
All-time high	$77.87
All-time high date	2025-03-21
All-time low	$2.43
All-time low date	2026-10-16
Average true range (ATR)	$0.70
Average volume	16.6K
Beta (1Y)	-1.09
Beta (2Y)	2.49
Beta (5Y)	2.73
Change from 52-week high	-61.91%
Change from 52-week low	64.2%
Change from all-time high	-95.04%
Change from all-time low	58.85%
Change from open	0%
Day's gap	12.39%
Dollar volume	$158,247
High price	$3.99
Low price	$3.99
Monthly RSI	33.15
Open price	$3.99
Premarket change	11.27%
Premarket close	$3.55
Premarket price	$3.95
Previous close	$3.55
Price vs 150-day SMA	-38.81%
Price vs 20-day SMA	-2.57%
Price vs 200-day SMA	-38.56%
Price vs 50-day SMA	-26.18%
Relative volume	2.38
Return from IPO open	-90.62%
Return from IPO price	18.33%
RSI	43.89
Sharpe ratio	0.01
Sortino ratio	0.08
Volume	39.7K
Weekly RSI	41.53
YTD price change	-39.43%
YTD total return	-39.43%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	910.3K
Float percentage	10.65%
Shares change (QoQ)	0.03%
Shares change (YoY)	571.61%
Shares held by insiders	2.78%
Shares held by institutions	3.56%
Shares outstanding	8.5M
Short % of float	3.31%
Short % of shares	0.35%
Short ratio	1.1 days

Deeper analysis on IBO

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this IBO report

Is a complete IBO research report available?

No complete published report is available for Impact BioMedical Inc. (IBO) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Impact BioMedical Inc. (IBO)

Price

Financial snapshot

Fair-value bridge

Latest news · IBO

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All IBO indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on IBO

Frequently asked questions